



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: HERDEIS-2

In re Application of:

CLAUS HERDEIS & CHRISTIAN EDWIN WEIS

Appl. No.: 10/616,587

Filed: July 10, 2003

For: METHOD OF TREATMENT FOR ACNE,
ROSACEA AND ULCERS WITH TAURILIDINE
AND/OR TAURULTAM IN A PHARMECEUTICAL
COMPOSITION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on September 5, 2003
(Date)

Ursula B. Day
(Name of Registered Representative)

[Signature]
Signature

Sept 5 2003
Date of Signature

S I R:

In accordance with 37 C.F.R. 1.56, applicant wishes to call the attention of the Examiner to the references as listed on enclosed form PTO-1449 most of which were cited in the instant specification and . Applicant does not admit that any of the cited documents constitutes prior art against the pending application.

Copies of these references are submitted herewith along with form PTO-1449. The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

- ☒ This Information Disclosure Statement is filed within three months of the filing date of a national application other than a continued prosecution application under 1.53(d), so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed within three months of the date of entry of the national stage as set forth in 1.491 in an international application, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed before the mailing of a first Office Action on the merits, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed after the issuance of a first office but before issuance of a final action under §1.113, or a notice of allowance under §1.311.
- ☐ This Information Disclosure Statement is submitted after the mailing of a final action or a notice of allowance, but before payment of the issue fee.
- ☐ The undersigned submits the following statement requesting consideration of this statement:

The undersigned hereby states:

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement;
- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.
- ☐ The fee of \$180.00 set forth in 1.17(p).
- ☐ The Commissioner is hereby authorized to charge the fee as set forth in 1.17(p), and any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.


The above-identified application discloses and claims an invention patentable over this prior art.

Docket No.: HERDEIS-2
Serial No.: 10/616,587


Entry of the references above set forth into the file of the above application is believed to be in order and is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

Respectfully submitted

By: 
Ursula B. Day
Attorney for Applicant
Reg. No. 47,296

Date: September 5, 2003
350 Fifth Avenue
Suite 4714
New York, N.Y. 10118
(212) 244-5500
UBD:be



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office**INFORMATION DISCLOSURE CITATION**

| | | |
|---|--|--------------------------------|
| Attorney's Docket N . HERDEIS-2 | Applicant CLAUS HERDEIS ET AL. | Appl. No. 10/616,587 |
| Filing Date July 10, 2003 | Group | Examiner |

U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date, if appropriate |
|------------------|-----------------|------------|------------------|-------|----------|-----------------------------|
| | 3,423,408 | 01-21-1969 | Pfaffmann | | | |
| | 5,889,183 | 03-30-1999 | Herdeis | | | |
| | 4,107,305 | 08-15-1978 | Pfaffmann | | | |
| | 4,337,251 | 06-29-1982 | Pfaffmann | | | |
| | 4,587,268 | 05-06-1986 | Pfaffmann | | | |
| | 4,604,391 | 08-05-1986 | Pfaffmann | | | |
| | 4,626,536 | 12-02-1986 | Pfaffmann | | | |
| | 4,772,468 | 09-20-1988 | Pfaffmann | | | |
| | 4,882,149 | 11-21-1989 | Spector | | | |
| | 6,251,896 | 06-26-2001 | Costin | | | |
| | 6,350,742 | 02-26-2002 | Costin | | | |
| | 6,436,926 | 08-20-2002 | Costin | | | |
| | 6,555,534 | 04-29-2003 | Costin | | | |
| | US2002/0049200 | 04-25-2002 | Calabresi et al. | | | |
| | 5,077,281 | 12-31-1991 | Reinmüller | | | |
| | US2002/0161003 | 10-31-2002 | Costin | | | |

FOREIGN PATENT DOCUMENTS

| Document Number | Date | Country | Class | Subclass | Translation |
|-----------------|------------|-------------|-------|----------|-------------|
| 482 713 | 01-30-1970 | Switzerland | | | No |
| 0 253 662 | 11-14-1990 | Europe | | | Yes |
| EP 1 066 830 | 01-10-2001 | Europe | | | Yes |
| WO 90/06138 | 06-14-1990 | PCT | | | Yes |
| WO 92/000743 | 01-23-1992 | PCT | | | Yes |
| WO 94/03174 | 02-17-1994 | PCT | | | Yes |
| WO 98/52572 | 11-26-1998 | PCT | | | Yes |
| DE 100 02 304 | 07-26-2001 | Germany | | | No |
| DE 198 14 358 | 10-07-1999 | Germany | | | No |
| DE 41 37 544 | 05-13-1993 | Germany | | | No |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|---|
| | Torres-Viera et al: "Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis, in: Antimicrobial Agents and Chemotherapy, June 2000, p. 1720-1724 |
| | "Arzneimittel und Therapie", in: Deutsche Apothekerzeitung, July 10, 21999. 43-46 |

Examiner:**Date considered:**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.